Sunshine Biopharma (SBFM) Intangibles (2015 - 2026)

Sunshine Biopharma's Intangibles history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Intangibles fell 39.94% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 39.94% YoY) and the FY2025 annual result came in at $1.9 million, down 37.43% from the prior year.
• Intangibles was $1.9 million for Q1 2026 at Sunshine Biopharma, up from $1.9 million in the prior quarter.
• Across five years, Intangibles topped out at $3.2 million in Q1 2025 and bottomed at $776856.0 in Q4 2022.
• A 5-year average of $2.0 million and a median of $2.0 million in 2025 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2024 — Intangibles soared 141.96% — and 2026, when it plunged 39.94%.
• Sunshine Biopharma's Intangibles stood at $776856.0 in 2022, then surged by 85.91% to $1.4 million in 2023, then jumped by 109.08% to $3.0 million in 2024, then slumped by 37.43% to $1.9 million in 2025, then climbed by 1.51% to $1.9 million in 2026.
• Business Quant data shows SBFM's Intangibles at $1.9 million in Q1 2026, $1.9 million in Q4 2025, and $2.0 million in Q3 2025.